Switch to:
Also traded in: Austria, Germany, Israel, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.05
MYL's Cash-to-Debt is ranked lower than
95% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. MYL: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
MYL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 4.17 Max: 49.83
Current: 0.05
0.02
49.83
Equity-to-Asset 0.37
MYL's Equity-to-Asset is ranked lower than
82% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYL: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
MYL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.83 Max: 0.94
Current: 0.37
0.19
0.94
Debt-to-Equity 1.11
MYL's Debt-to-Equity is ranked lower than
86% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. MYL: 1.11 )
Ranked among companies with meaningful Debt-to-Equity only.
MYL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.05 Max: 2.73
Current: 1.11
0.01
2.73
Debt-to-EBITDA 4.75
MYL's Debt-to-EBITDA is ranked lower than
78% of the 511 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. MYL: 4.75 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MYL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.22  Med: 4.72 Max: 7.4
Current: 4.75
3.22
7.4
Interest Coverage 2.40
MYL's Interest Coverage is ranked lower than
90% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 127.83 vs. MYL: 2.40 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.29 Max: 8.18
Current: 2.4
0.83
8.18
Piotroski F-Score: 6
Altman Z-Score: 1.33
Beneish M-Score: -2.62
WACC vs ROIC
9.67%
5.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 11.16
MYL's Operating Margin % is ranked higher than
59% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.71 vs. MYL: 11.16 )
Ranked among companies with meaningful Operating Margin % only.
MYL' s Operating Margin % Range Over the Past 10 Years
Min: 5.8  Med: 15.91 Max: 26.53
Current: 11.16
5.8
26.53
Net Margin % 7.28
MYL's Net Margin % is ranked higher than
55% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. MYL: 7.28 )
Ranked among companies with meaningful Net Margin % only.
MYL' s Net Margin % Range Over the Past 10 Years
Min: -3.53  Med: 8.88 Max: 13.48
Current: 7.28
-3.53
13.48
ROE % 7.16
MYL's ROE % is ranked higher than
51% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. MYL: 7.16 )
Ranked among companies with meaningful ROE % only.
MYL' s ROE % Range Over the Past 10 Years
Min: -14.72  Med: 14.08 Max: 29.99
Current: 7.16
-14.72
29.99
ROA % 2.46
MYL's ROA % is ranked lower than
54% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. MYL: 2.46 )
Ranked among companies with meaningful ROA % only.
MYL' s ROA % Range Over the Past 10 Years
Min: -2.47  Med: 4.52 Max: 7.1
Current: 2.46
-2.47
7.1
ROC (Joel Greenblatt) % 31.97
MYL's ROC (Joel Greenblatt) % is ranked higher than
76% of the 850 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.46 vs. MYL: 31.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.32  Med: 28.81 Max: 47.2
Current: 31.97
14.32
47.2
3-Year Revenue Growth Rate 6.70
MYL's 3-Year Revenue Growth Rate is ranked higher than
56% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MYL: 6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.1  Med: 15.2 Max: 54.5
Current: 6.7
-6.1
54.5
3-Year EBITDA Growth Rate 0.30
MYL's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. MYL: 0.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.4  Med: 11.1 Max: 107.9
Current: 0.3
-20.4
107.9
3-Year EPS without NRI Growth Rate -16.50
MYL's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. MYL: -16.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.1  Med: 8.1 Max: 110.4
Current: -16.5
-29.1
110.4
GuruFocus has detected 2 Warning Signs with Mylan NV MYL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYL's 30-Y Financials

Financials (Next Earnings Date: 2018-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

MYL Guru Trades in Q1 2017

Joel Greenblatt 648,342 sh (New)
Richard Pzena 7,262,316 sh (New)
Steven Cohen 3,602,271 sh (New)
Paul Tudor Jones 99,063 sh (+1701.15%)
First Pacific Advisors 5,349,600 sh (+73.37%)
Jim Simons 2,488,400 sh (+65.45%)
David Einhorn 8,692,307 sh (+0.25%)
Steven Cohen 40,000 sh (unchged)
John Paulson 200,000 sh (unchged)
Scott Black 40,821 sh (-0.05%)
Vanguard Health Care Fund 29,295,842 sh (-2.62%)
Mario Gabelli 14,500 sh (-12.19%)
John Paulson 17,274,387 sh (-16.15%)
Pioneer Investments 35,014 sh (-35.33%)
David Tepper 1,900,000 sh (-41.98%)
Lee Ainslie 1,545,448 sh (-59.32%)
» More
Q2 2017

MYL Guru Trades in Q2 2017

Steven Romick 6,341,690 sh (New)
Richard Pzena 12,339,687 sh (+69.91%)
First Pacific Advisors 8,187,380 sh (+53.05%)
Joel Greenblatt 833,660 sh (+28.58%)
David Einhorn 10,701,707 sh (+23.12%)
Mario Gabelli 14,501 sh (+0.01%)
Pioneer Investments 35,014 sh (unchged)
Vanguard Health Care Fund 29,295,842 sh (unchged)
John Paulson 200,000 sh (unchged)
Jim Simons Sold Out
David Tepper Sold Out
Lee Ainslie Sold Out
Scott Black Sold Out
Paul Tudor Jones Sold Out
John Paulson 15,933,600 sh (-7.76%)
Steven Cohen 802,548 sh (-77.72%)
» More
Q3 2017

MYL Guru Trades in Q3 2017

Diamond Hill Capital 15,980 sh (New)
Paul Tudor Jones 44,766 sh (New)
Steven Cohen 1,499,418 sh (+86.83%)
Richard Pzena 22,721,384 sh (+84.13%)
Steven Romick 7,425,690 sh (+17.09%)
First Pacific Advisors 9,469,120 sh (+15.66%)
Vanguard Health Care Fund 29,844,042 sh (+1.87%)
David Einhorn 10,744,307 sh (+0.40%)
Pioneer Investments 35,014 sh (unchged)
Mario Gabelli 14,500 sh (-0.01%)
John Paulson 14,718,600 sh (-7.63%)
Joel Greenblatt 63,497 sh (-92.38%)
» More
Q4 2017

MYL Guru Trades in Q4 2017

Leon Cooperman 237,000 sh (New)
Francisco García Paramés 223,489 sh (New)
Tom Russo 2,540 sh (New)
Pioneer Investments 399,037 sh (+1039.65%)
Joel Greenblatt 311,184 sh (+390.08%)
Steven Cohen 4,016,928 sh (+167.90%)
Diamond Hill Capital 17,383 sh (+8.78%)
First Pacific Advisors 9,509,860 sh (+0.43%)
Vanguard Health Care Fund 29,844,042 sh (unchged)
Steven Romick 7,425,690 sh (unchged)
Paul Tudor Jones Sold Out
Richard Pzena 21,978,042 sh (-3.27%)
David Einhorn 10,182,307 sh (-5.23%)
John Paulson 12,429,000 sh (-15.56%)
Mario Gabelli 6,500 sh (-55.17%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Pzena 2017-12-31 Reduce -3.27%0.12%$32.39 - $42.31 $ 41.288%21,978,042
John Paulson 2017-12-31 Reduce -15.56%1.3%$32.39 - $42.31 $ 41.288%12,429,000
David Einhorn 2017-12-31 Reduce -5.23%0.28%$32.39 - $42.31 $ 41.288%10,182,307
Joel Greenblatt 2017-12-31 Add 390.08%0.15%$32.39 - $42.31 $ 41.288%311,184
Leon Cooperman 2017-12-31 New Buy0.38%$32.39 - $42.31 $ 41.288%237,000
Mario Gabelli 2017-12-31 Reduce -55.17%$32.39 - $42.31 $ 41.288%6,500
Vanguard Health Care Fund 2017-09-30 Add 1.87%0.04%$29.63 - $39.49 $ 41.2821%29,844,042
Richard Pzena 2017-09-30 Add 84.13%1.72%$29.63 - $39.49 $ 41.2821%22,721,384
John Paulson 2017-09-30 Reduce -7.63%0.64%$29.63 - $39.49 $ 41.2821%14,718,600
David Einhorn 2017-09-30 Add 0.40%0.02%$29.63 - $39.49 $ 41.2821%10,744,307
Joel Greenblatt 2017-09-30 Reduce -92.38%0.42%$29.63 - $39.49 $ 41.2821%63,497
Mario Gabelli 2017-09-30 Reduce -0.01%$29.63 - $39.49 $ 41.2821%14,500
John Paulson 2017-06-30 Reduce -7.76%0.7%$36.72 - $40.09 $ 41.288%15,933,600
Richard Pzena 2017-06-30 Add 69.91%1.08%$36.72 - $40.09 $ 41.288%12,339,687
David Einhorn 2017-06-30 Add 23.12%1.26%$36.72 - $40.09 $ 41.288%10,701,707
Joel Greenblatt 2017-06-30 Add 28.58%0.1%$36.72 - $40.09 $ 41.288%833,660
Mario Gabelli 2017-06-30 Add 0.01%$36.72 - $40.09 $ 41.288%14,501
David Tepper 2017-06-30 Sold Out 1.22%$36.72 - $40.09 $ 41.288%0
Vanguard Health Care Fund 2017-03-31 Reduce -2.62%0.07%$35.81 - $45.28 $ 41.282%29,295,842
John Paulson 2017-03-31 Reduce -16.15%1.62%$35.81 - $45.28 $ 41.282%17,274,387
David Einhorn 2017-03-31 Add 0.25%0.01%$35.81 - $45.28 $ 41.282%8,692,307
Richard Pzena 2017-03-31 New Buy1.6%$35.81 - $45.28 $ 41.282%7,262,316
David Tepper 2017-03-31 Reduce -41.98%0.93%$35.81 - $45.28 $ 41.282%1,900,000
Joel Greenblatt 2017-03-31 New Buy0.32%$35.81 - $45.28 $ 41.282%648,342
Mario Gabelli 2017-03-31 Reduce -12.19%$35.81 - $45.28 $ 41.282%14,500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NSE:SUNPHARMA, NYSE:TEVA, TSE:4507, SHSE:600276, SHSE:600196, SZSE:000538, TSE:4523, SHSE:600518, NYSE:PRGO, TSE:4508, XPAR:IPN, NYSE:ZTS, OCSE:LUN, XSWX:VIFN, HKSE:03320, JSE:APN, SZSE:000963, SZSE:300122, SZSE:002001, SHSE:600085 » details
Traded in other countries:MYL.Austria, 6MY.Germany, MYL.Israel, MYL1.Switzerland, 0R5P.UK,
Headquarter Location:UK
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.

Mylan is the world's third- largest generic pharmaceutical manufacturer with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales comprise approximately 84% of revenue. Remaining sales come from a handful of branded products, primarily the epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

Guru Investment Theses on Mylan NV

John Keeley Comments on Mylan Labs - Apr 26, 2016

Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Top Ranked Articles about Mylan NV

Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
Detailed Research: Economic Perspectives on OUTFRONT Media, Mylan N.V, Axcelis Technologies, Patterson-UTI Energy, SAExploration, and vTv Therapeutics — What Drives Growth in Today's Competitive Landscape
What Did The World's Best Value Investors Buy Last Quarter? Top value investor buys according to 13F filings
What were value investors buying last quarter? According to 13F filings, which have to be filed by hedge funds with more than $100 million in assets under management every quarter (at the end of a 45 day period) despite the market elevated level towards the end of the year, some value investors were still adding and buying positions in their portfolios. Read more...
Francisco Garcia Parames Buys 19 Stocks in 4th Quarter Warren Buffett of Spain discloses portfolio
Often dubbed the “Warren Buffett (Trades, Portfolio) of Spain” for his value investing style, Spain’s Francisco Garcia Parames announced Friday that he bought 19 new stocks, giving his portfolio 30% turnover from the previous quarter. Read more...
Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018
Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine
Mylan to Complete $1 Billion Share Repurchase Plan

Ratios

vs
industry
vs
history
PE Ratio 25.33
MYL's PE Ratio is ranked higher than
54% of the 573 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.21 vs. MYL: 25.33 )
Ranked among companies with meaningful PE Ratio only.
MYL' s PE Ratio Range Over the Past 10 Years
Min: 7.32  Med: 26.53 Max: 112.56
Current: 25.33
7.32
112.56
Forward PE Ratio 7.70
MYL's Forward PE Ratio is ranked higher than
85% of the 73 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.67 vs. MYL: 7.70 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 25.33
MYL's PE Ratio without NRI is ranked higher than
54% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.28 vs. MYL: 25.33 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.32  Med: 26.53 Max: 112.56
Current: 25.33
7.32
112.56
Price-to-Owner-Earnings 38.40
MYL's Price-to-Owner-Earnings is ranked lower than
52% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.28 vs. MYL: 38.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.37  Med: 34.51 Max: 310
Current: 38.4
13.37
310
PB Ratio 1.67
MYL's PB Ratio is ranked higher than
75% of the 825 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. MYL: 1.67 )
Ranked among companies with meaningful PB Ratio only.
MYL' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.32 Max: 7.02
Current: 1.67
0.64
7.02
PS Ratio 1.86
MYL's PS Ratio is ranked higher than
69% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MYL: 1.86 )
Ranked among companies with meaningful PS Ratio only.
MYL' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.72 Max: 3.94
Current: 1.86
0.4
3.94
Price-to-Free-Cash-Flow 24.93
MYL's Price-to-Free-Cash-Flow is ranked higher than
53% of the 217 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.63 vs. MYL: 24.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.82  Med: 20.07 Max: 115.12
Current: 24.93
8.82
115.12
Price-to-Operating-Cash-Flow 11.55
MYL's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.74 vs. MYL: 11.55 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.07  Med: 11.6 Max: 40.9
Current: 11.55
6.07
40.9
EV-to-EBIT 26.64
MYL's EV-to-EBIT is ranked lower than
67% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.21 vs. MYL: 26.64 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.6  Med: 20.1 Max: 74.5
Current: 26.64
-10.6
74.5
EV-to-EBITDA 11.61
MYL's EV-to-EBITDA is ranked higher than
70% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. MYL: 11.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.5 Max: 23.3
Current: 11.61
-17.7
23.3
EV-to-Revenue 3.03
MYL's EV-to-Revenue is ranked higher than
54% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MYL: 3.03 )
Ranked among companies with meaningful EV-to-Revenue only.
MYL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 2.7 Max: 5.6
Current: 3.03
1.5
5.6
PEG Ratio 6.02
MYL's PEG Ratio is ranked lower than
83% of the 313 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.88 vs. MYL: 6.02 )
Ranked among companies with meaningful PEG Ratio only.
MYL' s PEG Ratio Range Over the Past 10 Years
Min: 0.72  Med: 2.97 Max: 13.61
Current: 6.02
0.72
13.61
Shiller PE Ratio 103.30
MYL's Shiller PE Ratio is ranked lower than
86% of the 216 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.75 vs. MYL: 103.30 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.48  Med: 84.16 Max: 169.02
Current: 103.3
14.48
169.02
Current Ratio 1.46
MYL's Current Ratio is ranked lower than
73% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. MYL: 1.46 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 4.68 Max: 11.71
Current: 1.46
0.83
11.71
Quick Ratio 0.95
MYL's Quick Ratio is ranked lower than
78% of the 812 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.88 vs. MYL: 0.95 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.47 Max: 8.47
Current: 0.95
0.55
8.47
Days Inventory 131.88
MYL's Days Inventory is ranked lower than
57% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.37 vs. MYL: 131.88 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 133.92 Max: 168.24
Current: 131.88
88.95
168.24
Days Sales Outstanding 86.31
MYL's Days Sales Outstanding is ranked lower than
57% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.67 vs. MYL: 86.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.49  Med: 86.72 Max: 107.26
Current: 86.31
77.49
107.26
Days Payable 41.00
MYL's Days Payable is ranked lower than
78% of the 630 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.56 vs. MYL: 41.00 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 41  Med: 70.84 Max: 101.21
Current: 41
41
101.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.90
MYL's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.00 vs. MYL: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -1 Max: 7.4
Current: -12.9
-25.8
7.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.11
MYL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. MYL: 1.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.57 Max: 5.33
Current: 1.11
0.62
5.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.37
MYL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
74% of the 85 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. MYL: 2.37 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MYL' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.46  Med: 1.77 Max: 7.86
Current: 2.37
0.46
7.86
Price-to-Median-PS-Value 1.08
MYL's Price-to-Median-PS-Value is ranked higher than
52% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.05 vs. MYL: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 2.24 Max: 8.34
Current: 1.08
0.38
8.34
Earnings Yield (Greenblatt) % 3.75
MYL's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 868 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.18 vs. MYL: 3.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.7  Med: 4.5 Max: 19
Current: 3.75
-15.7
19
Forward Rate of Return (Yacktman) % 9.01
MYL's Forward Rate of Return (Yacktman) % is ranked lower than
51% of the 411 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.51 vs. MYL: 9.01 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 13.05 Max: 24.9
Current: 9.01
7.8
24.9

More Statistics

Revenue (TTM) (Mil) $11,936.60
EPS (TTM) $ 1.63
Beta1.39
Short Percentage of Float4.03%
52-Week Range $29.39 - 47.82
Shares Outstanding (Mil)536.44

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 12,018 12,526 13,128 13,513
EBIT (Mil $) 2,576 3,101 4,262
EBITDA (Mil $) 3,549 3,962 4,298 4,302
EPS ($) 4.54 5.35 5.94 6.16
EPS without NRI ($) 4.54 5.35 5.94 6.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.23%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}